相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease
Lampros Chrysavgis et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Burden of Disease due to Nonalcoholic Fatty Liver Disease
Mark D. Muthiah et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2020)
Current management of non-alcoholic steatohepatitis
Mark D. Muthiah et al.
LIVER INTERNATIONAL (2020)
Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
Eugene Han et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
Kota Yano et al.
DIAGNOSTICS (2020)
Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Yumie Takeshita et al.
DIABETES THERAPY (2020)
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study
Tomoe Kinoshita et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Limitations of non-invasive tests for assessment of liver fibrosis
Keyur Patel et al.
JHEP REPORTS (2020)
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
Masanori Shimizu et al.
DIABETES OBESITY & METABOLISM (2019)
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira et al.
DRUGS (2019)
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease
Yoshimasa Aso et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2019)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease A Systematic Review and Meta-analysis
Dimitrios A. Koutoukidis et al.
JAMA INTERNAL MEDICINE (2019)
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
Mitsuko Inoue et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes et al.
HEPATOLOGY (2018)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas et al.
DIABETOLOGIA (2018)
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
Mohammad Shadab Siddiqui et al.
HEPATOLOGY (2018)
Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
Boyu Li et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2018)
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
Debapriya Basu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
Toshio Itani et al.
OBESITY SCIENCE & PRACTICE (2018)
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study
Takashi Shibuya et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
Yuya Seko et al.
HEPATOLOGY RESEARCH (2017)
Liver Fat, Hepatic Enzymes, Alkaline Phosphatase and the Risk of Incident Type 2 Diabetes: A Prospective Study of 132,377 Adults
Sean Chun-Chang Chen et al.
SCIENTIFIC REPORTS (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
Basement Membrane Type IV Collagen and Laminin: An Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease
Ki M. Mak et al.
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY (2017)
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects
Takahiro Takase et al.
ENDOCRINE JOURNAL (2017)
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults
Andrea Marengo et al.
CLINICS IN LIVER DISEASE (2016)
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Non-alcoholic fatty liver disease and diabetes
Jonathan M. Hazlehurst et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Hepatic steatosis and fibrosis: Non-invasive assessment
Rustam N. Karanjia et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
Stuart McPherson et al.
JOURNAL OF HEPATOLOGY (2015)
Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?
Nozomi Takeshima et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
Xiang Wan et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
Lifestyle-Induced Decrease in Fat Mass Improves Adiponectin Secretion in Obese Adults
Karen R. Kelly et al.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2014)
Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score, and the Risk of Incident Diabetes in a Korean population
Yoosoo Chang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease
Mikako Obika et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
Rachel M. Williamson et al.
DIABETES CARE (2011)
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease
Yoshio Sumida et al.
JOURNAL OF GASTROENTEROLOGY (2011)
Molecular mechanisms involved in hepatic steatosis and insulin resistance
Takashi Matsuzaka et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
Mariana Lazo et al.
DIABETES CARE (2010)
NONALCOHOLIC FATTY LIVER DISEASE Liver disease: an overlooked complication of diabetes mellitus
Marco Arrese
NATURE REVIEWS ENDOCRINOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
Leena Juurinen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease
M Hamaguchi et al.
ANNALS OF INTERNAL MEDICINE (2005)
分享论文
